- Home
- ENTA vs CRGX Comparison
ENTA vs CRGX Comparison
Compare ENTA & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CRGX
- Stock Information
- Founded
- ENTA 1995
- CRGX 2021
- Country
- ENTA United States
- CRGX United States
- Employees
- ENTA N/A
- CRGX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- ENTA Health Care
- CRGX
- Exchange
- ENTA Nasdaq
- CRGX Nasdaq
- Market Cap
- ENTA 160.3M
- CRGX 190.0M
- IPO Year
- ENTA 2013
- CRGX 2023
- Fundamental
- Price
- ENTA $7.28
- CRGX $4.27
- Analyst Decision
- ENTA Buy
- CRGX Hold
- Analyst Count
- ENTA 4
- CRGX 7
- Target Price
- ENTA $18.00
- CRGX $4.67
- AVG Volume (30 Days)
- ENTA 168.6K
- CRGX 647.1K
- Earning Date
- ENTA 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- ENTA N/A
- CRGX N/A
- EPS Growth
- ENTA N/A
- CRGX N/A
- EPS
- ENTA N/A
- CRGX N/A
- Revenue
- ENTA $64,462,999.00
- CRGX N/A
- Revenue This Year
- ENTA N/A
- CRGX $58.18
- Revenue Next Year
- ENTA $0.48
- CRGX N/A
- P/E Ratio
- ENTA N/A
- CRGX N/A
- Revenue Growth
- ENTA N/A
- CRGX N/A
- 52 Week Low
- ENTA $4.09
- CRGX $3.00
- 52 Week High
- ENTA $17.24
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ENTA 60.14
- CRGX 45.02
- Support Level
- ENTA $6.87
- CRGX $4.33
- Resistance Level
- ENTA $8.47
- CRGX $4.48
- Average True Range (ATR)
- ENTA 0.50
- CRGX 0.19
- MACD
- ENTA -0.03
- CRGX -0.02
- Stochastic Oscillator
- ENTA 54.44
- CRGX 21.14
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.